GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

DNA analysis company 23andme has been in trouble lately: data was breached in a 2023 hack, and this September the entire ...

Fortune noted that among the 55 women currently leading Fortune 500 companies, Barra is one of only nine who have been CEO ...

After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious ...

DNA submitted by users to the genealogy company 23andMe will remain private for now, with CEO Anne Wojcicki saying she no ...

An activist invester has taken interest in pharma giant Pfizer, which despite becoming a household name during the pandemic ...

With a user base of more than 94 million—larger than the population of Germany—GCash is arguably the most popular Filipino ...

GlaxoSmithKline (GSK) appears to be focusing more on finding a new CEO than any large M&A deals after last year's $20 billion asset swap with Novartis, according to a briefing following strong Q1 ...

The idea is that if you move your focus to attracting people, you’ll ultimately attract the companies: If you build it (the ...

Chris Martin, Chairman and Non Executive Director of Myricx Bio said, “I am delighted to welcome Paolo to the board. He brings extensive leadership experience in R&D and commercialisation in the ...

McNamara has been with GSK since 2015, when he joined the company as head of consumer health for Europe and the Americas, and previously worked for 10 years at Novartis, ultimately heading up its ...